EUVIMEDEUVIMED entdecken
Crossref

EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non–Small Cell Lung Cancer

Willdragon Wang iD, Dylan G Scholes, Alex C Watts, Megan A Roy iD, Sunil Singhal, John C Kucharczuk, Doraid Jarrar, Jarrod Predina, Taine T V Pechet, Lova L Sun iD, Aditi P Singh, Roger B Cohen und 3 weitere

JCO Precision Oncology · 2026-07 · 10 (7)

DOI: 10.1200/po-25-01207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Willdragon Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Electronic Health Records. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Adjuvant targeted therapies and perioperative chemoimmunotherapy have made it imperative to perform molecular testing in early-stage nonsquamous (NSq) non–small cell lung cancer (NSCLC). We present a prospective clinical trial evaluating an electronic medical record (EMR)–based nudge intervention to promote timely completion of comprehensive molecular testing (cMT) in patients with early-stage NSq NSCLC. METHODS The EMBER-Lung trial prospectively enrolled patients undergoing surgical resection. The intervention included an EMR-based nudge at the time of the first postoperative visit, prompting the clinician to accept an order for cMT if NSq NSCLC histology. Following completion of cMT, if an actionable alteration was found, a reflex alert summarizing therapeutic options was sent to the patient's care team. The primary end point was the proportion of patients who underwent cMT in the real-world control and nudge intervention cohorts. Clinical characteristics and outcomes of the control and nudge intervention cohorts were compared using Pearson Chi-squared test, Fisher exact test, or Z score. RESULTS Between July 2021 and November 2023, 460 patients were included (243 nudge and 217 control patients). The median age was 68.4 years, 64.3% female; 74.1% had a smoking history and mostly stage I (I/II/III; 75.9%, 14.1%, 10.0%, respectively). The proportion of patients with cMT increased in the nudge intervention (80/217, 36.9% v 197/243, 81.1%, P < .00001) across all stages (I to III). A greater proportion of patients with classical EGFR mutations and KRAS G12C mutations were detected in the nudge intervention setting ( EGFR : 14/217, 6.5% v 41/243, 16.9%, P < .001; KRAS G12C: 12/217, 5.5%, v 33/243, 13.6%, P < .01). CONCLUSION In well-matched control and nudge intervention cohorts, an EMR-based nudge after resection of early-stage NSq NSCLC was feasible and increased the proportion of patients with cMT. Future research will incorporate this earlier, at the time of biopsy, to inform neoadjuvant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsElectronic Health RecordsHumansFemaleMaleAgedProspective StudiesMiddle AgedNeoplasm Staging

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA.
  • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
  • Division of Thoracic Surgery, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Willdragon Wang, Megan A Roy, Lova L Sun, Charu Aggarwal, Melina E Marmarelis

Zitieren

APA

Wang, W., Scholes, D. G., Watts, A. C., Roy, M. A., Singhal, S., Kucharczuk, J. C., Jarrar, D., Predina, J., Pechet, T. T. V., Sun, L. L., Singh, A. P., Cohen, R. B., Langer, C. J., Aggarwal, C., & Marmarelis, M. E. (2026). EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non–Small Cell Lung Cancer. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-01207

Vancouver

Wang W, Scholes DG, Watts AC, Roy MA, Singhal S, Kucharczuk JC, et al. EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non–Small Cell Lung Cancer. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-01207

BibTeX
@article{Wang2026,
  author = {Wang, Willdragon and Scholes, Dylan G and Watts, Alex C and Roy, Megan A and Singhal, Sunil and Kucharczuk, John C and Jarrar, Doraid and Predina, Jarrod and Pechet, Taine T V and Sun, Lova L and Singh, Aditi P and Cohen, Roger B and Langer, Corey J and Aggarwal, Charu and Marmarelis, Melina E},
  title = {EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non–Small Cell Lung Cancer},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {7},
  doi = {10.1200/po-25-01207}
}
Kostenlos starten →